title: In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
abstract: OBJECTIVE
  Telavancin is a novel semi-synthetic lipoglycopeptide currently in late-stage clinical development for the treatment of serious infections due to Gram-positive bacteria. The objective of this study was to provide a baseline prospective assessment of its in vitro activity against a large and diverse collection of Gram-positive clinical isolates from Europe and Israel.
  
  
  METHODS
  Gram-positive clinical isolates, collected between October 2004 and December 2005 from 36 hospital laboratories in 15 countries, were tested by broth microdilution using CLSI methodology.
  
  
  RESULTS
  In total, 3206 isolates were collected. Telavancin had potent activity against Staphylococcus aureus and coagulase-negative staphylococci (MIC range < or =0.015 to 2 mg/L), independent of resistance to methicillin or to multiple drugs. Telavancin had particularly strong activity against streptococcal isolates (MIC range < or =0.001 to 0.5 mg/L), including penicillin-resistant and multiple drug-resistant Streptococcus pneumoniae and erythromycin non-susceptible beta-haemolytic and viridans group streptococci. Telavancin also had excellent activity against vancomycin-susceptible enterococci (MIC(90) 0.5 mg/L), and although its MICs were elevated against VanA strains (Enterococcus faecalis MIC(90) 8 mg/L and Enterococcus faecium MIC(90) 4 mg/L), its MIC(90) was substantially lower than observed with available glycopeptides.
  
  
  CONCLUSIONS
  Telavancin has potent in vitro activity against contemporary Gram-positive clinical isolates from diverse geographic areas in Europe and Israel.
authors.affiliation: Eurofins Medinet, Inc., 13665 Dulles Technology Drive, Suite 200, Herndon, VA, USA.
authors.forename: Deborah C
authors.initials: DC
authors.lastname: Draghi
authors.forename: Bret M
authors.initials: BM
authors.lastname: Benton
authors.forename: Kevin M
authors.initials: KM
authors.lastname: Krause
authors.forename: Clyde
authors.initials: C
authors.lastname: Thornsberry
authors.forename: Chris
authors.initials: C
authors.lastname: Pillar
authors.forename: Daniel F
authors.initials: DF
authors.lastname: Sahm
mesh_terms: D000328:Adult; D000617:Aminoglycosides / Q000494:pharmacology*; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D005060:Europe; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification*; D016908:Gram-Positive Bacterial Infections / Q000382:microbiology*; D006801:Humans; D007557:Israel; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000077427:Lipoglycopeptides; C487637:telavancin